

16c
gms
4-12-60

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

NI *et al.*

Appl. No. 09/448,868

Filed: November 24, 1999

For: **Death Domain Containing
Receptor-4 Antibodies**


Confirmation No. 5546

Art Unit: 1646

Examiner: Kaufman, C.

Atty. Docket:
1488.1300004/EKS/EJH/TAC

RECEIVED
MAR 04 2002
TECH CENTER 1600/2900



Amendment and Reply Under 37 C.F.R. § 1.111

Commissioner for Patents
Washington, D.C. 20231

Sir:

In reply to the Office Action dated **November 26, 2001**, Applicants submit the following Amendment and Remarks. This Amendment is provided in the following format:

- (A) A clear version of each replacement paragraph/section/claim along with clear instructions for entry;
- (B) Starting on a separate page, appropriate remarks and arguments. 37 C.F.R. § 1.111 and MPEP 714; and
- (C) Starting on a separate page, a marked-up version entitled: "Version with markings to show changes made."

It is not believed that extensions of time or fees for net addition of claims are required beyond those that may otherwise be provided for in documents accompanying this paper. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R.

05/04/2002 INJULDER1 00000129 09440060

01 50:102
02 50:103

672.00 DP
1854.00 DP

C